This announcement is a separate document:
Chimeric Therapeutics Ltd: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.